Rationale and dose-finding studies of the combination of irinotecan and a taxane on a weekly schedule

ONCOLOGY

Volumn 15, Issue 1 SUPPL. 1, 2001, Pages 25-30

  Murren, John R ^c   Blum, Kathleen ^a   Gallipoli, Marianne ^b   Mckeon, Anne ^a   Rich, Randy ^b  

^a YALE CANCER CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BRIDGED COMPOUND; CAMPTOTHECIN; CISPLATIN; DRUG DERIVATIVE; IRINOTECAN; TAXANE; TAXOID;

ADULT; AGED; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MIDDLE AGED; PROGNOSIS; REVIEW; SMALL CELL CARCINOMA; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRIDGED COMPOUNDS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; TAXOIDS;

EID: 0035221149     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Rowinsky EK, Donehower RC: Paclitaxel (Taxol). New Engl J Med 332:1004-1014, 1995.
2. Bonomi P, Kim K, Fairclough D, et al: Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 18:623-631, 2000.
3. Belani CP, Natale RB, Lee JS, et al: Randomized phase III trial comparing cisplatin/etoposide versus carboplatin/paclitaxel in advanced and metastatic non-small cell lung cancer (NSCLC) (abstract 1751 ). Proc Am Soc Clin Oncol 17:455a, 1998.
4. Kelly K, Crowley J, Bunn PA, et al: A randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated advanced non-small cell lung cancer (NSCLC): A Southwest Oncology Group (SWOG) trial (abstract 1777). Proc Am Soc Clin Oncol 18:461a, 1999.
5. Schiller JH, Harrington D, Sandler A, et al: A radomized phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC) (abstract 2). Proc Am Soc Clin Oncol 19:la, 2000.
6. Shepherd FA, Dancey J, Ramlau R, et al: Prospective randomized trial of docetaxel versus best supportive care in patients with non-smallcell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095-2103, 2000.
7. Dancey J, Shepherd F, Ramlau R, et al: Quality of life (QOL) assessment in a randomized study of taxotere (TAX) versus best supportive care (BSC) in non-small cell lung cancer (NSCLC) patients (pts) previously treated with platinum-based chemotherapy (abstract 1896). Proc Am Soc Clin Oncol 18:491a, 1999.
8. Fossella FV, DeVore R, Kerr RN, et al: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18:2354-2362, 2000.
9. Miller VA, Fossella FV, DeVore R, et al: Docetaxel (D) benefits lung cancer symptoms and quality of life (QoL) in a randomized phase III study of non-small cell lung cancer (NSCLC) patients previously treated with platinum-treated therapy (abstract 1895). Proc Am Soc Clin Oncol 18:491a, 1999.
10. Ettinger DS, Finkelstein DM, Sarma RP, et al: Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 13:1430-1435, 1995.
11. Kirschling RJ, Grill JP, Marks RS, et al: Paclitaxel and G-CSF in previously untreated patients with extensive stage small-cell lung cancer: A phase II study of the North Central Cancer Treatment Group. Am J Clin Oncol 22:517-522, 1999.
12. Smit EF, Fokkema E, Biesma B, et al: A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br J Cancer 77:347-351, 1998.